Second-Generation CLL Inhibitors How could patients benefit from second-generation CLL inhibitors? CLL experts Dr. Nicole Lamanna and Dr. Philip Thompson explore the top three reasons researchers continue to push the envelope on inhibitors: safety, decreased side effects, and improved efficacy. Learn why Dr. Thompson describes clinical trials of second-generation medications as “more elegant, more refined.” Get email alerts | Subscribe on YouTube | Like on Facebook | Follow on Twitter | Follow on Google+ |